Company Profile
Phathom Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- PHAT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
9.28 USD (-3.13%)
Close
Last updated: August 17, 2026
770M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, PHAT closed down 3.13% at $9.28. No new same-company headline was identified in the current news window.
Company overview
Gastrointestinal Medicines
Phathom Pharmaceuticals develops and commercializes treatments for acid-related gastrointestinal diseases. It holds U.S., European and Canadian rights to vonoprazan, a potassium-competitive acid blocker.
VOQUEZNA Franchise
VOQUEZNA is marketed in the United States for heartburn associated with non-erosive gastroesophageal reflux disease, healing and maintenance of erosive GERD, and as dual- or triple-drug packs for Helicobacter pylori infection. Its mechanism provides rapid and durable acid suppression distinct from proton-pump inhibitors.
Eosinophilic Esophagitis Development
The Phase 2 pHalcon-EoE-201 trial is evaluating VOQUEZNA in eosinophilic esophagitis. This program tests whether strong acid suppression can benefit a chronic inflammatory esophageal disease and extend the franchise into another specialist-treated indication.
Future catalysts
- Topline results from the Phase 2 pHalcon-EoE-201 trial expected in late fourth-quarter 2026 or early first-quarter 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Phathom Pharmaceuticals (PHAT)?
Phathom Pharmaceuticals (PHAT) most recently closed at 9.28 USD, a -3.13% move versus the previous session.
What is the market cap of Phathom Pharmaceuticals (PHAT)?
Phathom Pharmaceuticals currently has a market capitalization of 770M USD on BioPharmSignal.
What does Phathom Pharmaceuticals do?
Gastrointestinal Medicines Phathom Pharmaceuticals develops and commercializes treatments for acid-related gastrointestinal diseases. It holds U.S., European and Canadian rights to vonoprazan, a potassium-competitive acid blocker. VOQUEZNA Franchise VOQUEZNA is marketed in the United States for heartburn associated with non-erosive gastroesophageal reflux...
On which exchange is PHAT stock listed?
Phathom Pharmaceuticals (PHAT) is associated with NASDAQ, United States, Biopharma.
What is Gastrointestinal?
Gastrointestinal Medicines Phathom Pharmaceuticals develops and commercializes treatments for acid-related gastrointestinal diseases.
Which conditions is Phathom Pharmaceuticals targeting with Gastrointestinal?
Gastrointestinal Medicines Phathom Pharmaceuticals develops and commercializes treatments for acid-related gastrointestinal diseases. It holds U.S., European and Canadian rights to vonoprazan, a potassium-competitive acid blocker. VOQUEZNA Franchise VOQUEZNA is marketed in the United States for heartburn associated with non-erosive gastroesophageal reflux...
How does Phathom Pharmaceuticals describe recent progress with Gastrointestinal?
Topline results from the Phase 2 pHalcon-EoE-201 trial expected in late fourth-quarter 2026 or early first-quarter 2027.
What is Medicines?
Gastrointestinal Medicines Phathom Pharmaceuticals develops and commercializes treatments for acid-related gastrointestinal diseases.